WUXI XDC (02268) announced its interim results. The adjusted net profit attributable to shareholders is approximately 1.027 billion yuan, a year-on-year increase of 37.4%.

WUXI XDC (02268) announced its mid-2026 results, with revenues of approximately 3.701 billion yuan, representing a year-on-year growth of 37.04%. Excluding the impact of foreign exchange fluctuations, the CER grew by 41.5% year-on-year. Gross profit was approximately 1.371 billion yuan, an increase of 40.6% year-on-year; the adjusted net profit attributable to shareholders was approximately 1.027 billion yuan, a year-on-year increase of 37.4%; and the profit attributable to shareholders was approximately 819 million yuan, a year-on-year increase of 9.87%. Basic earnings per share were 0.65 yuan. Excluding revenues from Dongyao Pharmaceutical, WUXI XDC's independent revenue reached 3.556 billion yuan, with an AER growth of 31.7%. Excluding the impact of foreign exchange fluctuations, the CER grew by 36.2% year-on-year. During the reporting period, WUXI XDCs independent gross profit was about 1.337 billion yuan, reflecting a year-on-year increase of 37.1%. The independent gross profit margin increased from 36.1% to 37.6%. WUXI XDC's independent adjusted net profit rose to approximately 1.028 billion yuan, a year-on-year growth of 37.5%. The independent adjusted net profit margin improved from 27.7% to 28.9%. The announcement stated that the increase in revenue was primarily due to (i) the ongoing active development of the global ADC and broader bioconjugate drug market, which drove an increase in the number of customers and projects; (ii) the Groups solid position as a leading ADC CRDMO service provider, which enhanced its market share; and (iii) the steady advancement of the Groups projects to later stages (which typically result in higher contract values). During the reporting period, supported by the "Empowering, Following, and Winning Molecules" strategy, the Groups ADC CRDMO business continued to grow. The Group continued to support comprehensive ADC and bioconjugate drug projects through its bioconjugate drug platform and global operations. During the reporting period, new project signings reached a historical high. This reflects the ongoing vitality of upstream research and development and provides further momentum for the sustained high growth of the bioconjugate drug industry.